Several biomarkers were reported as predictors for NSCLC patients receiving adjuvant chemotherapies, such as βIII tubulin, ERCC1, p27, p53, Ras, and Id1 [18, 41-43]. Here, ERCC1 is linked to non-small cell lung carcinoma.